A Phase 1/2 interventional study of BIO 300 Oral Suspension and Paclitaxel in Carcinoma, Non-Small-Cell Lung, sponsored by Humanetics Corporation. Completed at 4 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-01-25.
Sponsored by Humanetics Corporation · Phase 1/2, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 3,368 studies in Carcinoma, Non-Small-Cell Lung with a site in United States — 519 open to participants now, 894 under way, 142 of them phase 3. Carcinoma, Non-Small-Cell Lung · United States.
Among the 3,368 studies in Carcinoma, Non-Small-Cell Lung with a site in United States, this one is the 2,263rd largest by enrollment of the 2,995 interventional ones that give a count, is one of 170 that started in 2015, is one of 484 in phase 1/2, and was the 1,604th registered.
7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.
Browse Carcinoma, Non-Small-Cell Lung studies →519 of the 3,368 studies in Carcinoma, Non-Small-Cell Lung with a site in United States are open now. Recruiting first, the newest first:
National Cancer Institute (NCI) · Sites in United States
Ages 18+
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Sites in United States
Ages 18+
Indiana University · Sites in United States
Ages 18+
Exelixis · Sites in United States
Ages 18+
University of Chicago · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
3,368 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1,411 · Phase 2 1,591 · Phase 3 382 · Phase 4 13
First in 1990; this study’s year is marked. 170 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 21 is below the median of 62 across 6,024 interventional studies indexed under Carcinoma, Non-Small-Cell Lung.
Median enrollment 56 across the 2,995 interventional studies, 100 across the 246 observational. Of the 2,297 that completed or were terminated, 1,053 (46%) have results posted.
This tab as a report to print or save as PDF → With an account.
1,736 of 3,368 have an industry lead sponsor. The 10 most frequent:
Humanetics Corporation is the lead sponsor of 7 studies on the registry; none are open to participants now.
Humanetics Corporation has 1 study filed under Carcinoma, Non-Small-Cell Lung — fewer than ten, so there is no comparison to draw.
272 of the studies in Carcinoma, Non-Small-Cell Lung with a site in United States that are under way reach primary completion within a year, 25 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05987956Phase 3Medicine Invention Design, IncPharmacogenomics IND SNP Clinical Trial - Alectinib and Single Nucleotide Polymorphisms | 2026-11-18 |
| NCT03815643Phase 3EMD Serono Research & Development Institute, Inc.Avelumab Program Rollover Study | 2026-11-24 |
| NCT04585490Phase 3Stanford UniversityAdaptive ctDNA-Based Personalization of Treatment During Consolidation Therapy in NSCLC | 2026-12 |
| NCT03637816Phase 3M.D. Anderson Cancer CenterAnamorelin Hydrochloride in Reducing Anorexia in Patients With Advanced Non-small Cell Lung Cancer | 2026-12-31 |
| NCT05221840Phase 3AstraZenecaA Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer | 2027-01-08 |
Add all 272 to your calendar (.ics) → With an account.
Among the 3,368 studies in Carcinoma, Non-Small-Cell Lung with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine the safety and effectiveness of BIO 300 Oral Suspension when used in combination with standard dose radiation therapy and chemotherapy in patients with non-small cell lung cancer. Based on preclinical data the investigators hypothesize that BIO 300 Oral Suspension will reduce the incidence of radiation-induced pneumonitis and pulmonary fibrosis.
This is an open-label, single-arm, ascending dose Phase I/II study of BIO 300 Oral Suspension given in combination with paclitaxel/carboplatin and radiotherapy in subjects with stage II, III, or IV NSCLC who are candidates for combined chemoradiotherapy.
A minimum of 6 subjects will be accrued sequentially at each dose level of BIO 300. BIO 300 will be administered daily for the entire course of concurrent chemoradiotherapy, a minimum of 6 weeks; in combination with standard paclitaxel / carboplatin chemotherapy and radiotherapy.
The initial dose of BIO 300 will be administered on Day 1, Visit 2 in which safety data (adverse events, electrocardiograms (ECGs), results of safety laboratory determinations), pharmacokinetic (PK) and pharmacodynamic (PD) data will be collected. PK data will be collected from a minimum of six (6) study subjects from each cohort. PD data will be collected from all subjects in each study cohort. Day 1 of chemotherapy will be scheduled at the discretion of the investigator provided the subject has completed a minimum of 1 day of BIO 300 dosing. BIO 300 will be administered in combination with the chemotherapy components of the protocol (paclitaxel and carboplatin). During the first or second chemotherapy infusion, additional safety, PK and PD data will be collected. Day 1 of radiation therapy (RT) may be scheduled at the discretion of the investigator provided the subject has completed a minimum of 2 days of BIO 300 dosing. BIO 300 will continue to be administered daily; paclitaxel and carboplatin will be administered weekly and radiotherapy will be administered daily until a total dose of 60-70 Gy has been administered. During the period of combined BIO 300 and chemoradiotherapy (6-7 weeks), additional safety, PK and PD data will be collected weekly. An interim data analysis will be completed once the highest dose cohort concludes chemoradiation therapy, in an effort to determine the optimal biological dose. Following analysis, there will be an option to enroll up to an additional 12 subjects at the optimal biological dose. At the conclusion of the study, primary and secondary outcome measures will be evaluated. Data will be analyzed from all cohorts to determine the oncologic response, safety of BIO 300, and a recommended BIO 300 dose.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients with any of the following are not eligible:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ascending dose evaluation of BIO 300 Oral Suspension (3 dose levels) given in combination with paclitaxel/carboplatin and radiotherapy.
Drug: BIO 300 Oral Suspension · Drug: Paclitaxel · Drug: Carboplatin · Radiation: Radiotherapy
Cohort 1: BIO 300 500 mg Cohort 2: BIO 300 1,000 mg Cohort 3: BIO 300 1,500 mg Cohort 4: BIO 300 Optimal dose (TBD) BIO 300 dose will be given daily, 7 days/week (Week 1, day 1 through week 6) The 2nd and 3rd dosing cohort (1,000 and 1,500 mg/day) will begin following the accrual of a minimum of 6 subjects at the previous dose level, dose escalation to the next BIO 300 dose level will be allowed to occur when a cohort has completed concurrent chemoradiotherapy with fewer than 33% Dose Limiting Toxicities (DLTs) attributed to BIO 300 Oral Suspension.
Also known as: genistein, 5, 7-dihydroxy-3-(4-hydroxyphenyl)-chromen-4-one
During the Concurrent Therapy period, paclitaxel 45 mg/m2 will be administered by intravenous drip weekly during weeks 1-6. During the Consolidation Therapy period, paclitaxel 200 mg/m2 will be administered by intravenous drip two times, 21 days apart.
Also known as: Onxol, Taxol
During the Concurrent Therapy period, area under the curve (AUC) = 2mg\* min/mL will be administered by intravenous drip weekly during weeks 1-6. During the Consolidation Therapy period, carboplatin AUC = 6mg\*min/mL will be administered by intravenous drip two times, 21 days apart.
Also known as: Paraplatin, CARBOplatin Novaplus
Radiation treatment will be scheduled at the discretion of the investigator provided the subject has completed a minimum of 2 days of BIO 300 dosing. Subjects will receive radiation therapy 5 days per week, once daily fractions, 1.8-2.0 Gy per fraction, for 6-7 weeks.
Number of Participants With BIO 300 Oral Suspension-related Dose Limiting Toxicity
Adverse events of CTCAE v4.0 grade 3 or higher that were possibly, probably or definitely related to BIO 300 Oral Suspension and have occurred before or during concurrent chemoradiotherapy were considered dose limiting toxicities.
Time frame: Day 1 up to 6 weeks or maximum tolerated dose
Number of Participants With Adverse Events Throughout the Study
Time frame: Day 1 up to month 13 post radiation or 12 months post chemotherapy consolidation for surgical participants.
Mean Maximum Serum Concentration (Cmax) of BIO 300 Administered in the Absence of Chemotherapy
Time frame: Day 1, prior to 1st dose then 0.5, 1, 2, 3, 4, 8 and 24 hours post dose
Mean Area Under the Serum Concentration Curve (AUC) of BIO 300 Administered in the Absence of Chemotherapy
Time frame: Day 1, prior to 1st dose then 0.5, 1, 2, 3, 4, 8 and 24 hours post dose
Mean Maximum Serum Concentration (Cmax) of BIO 300 When Administered in Combination With Paclitaxel and Carboplatin
Time frame: Week 1 or 2, during the 1st or 2nd chemotherapy infusion, prior to 1st dose then 0.5, 1, 2, 3, 4, 8, and 24 hours post dose
Mean Area Under the Serum Concentration Curve (AUC) of BIO 300 When Administered in Combination With Paclitaxel and Carboplatin
Time frame: Week 1 or 2, during the 1st or 2nd chemotherapy infusion, prior to 1st dose then 0.5, 1, 2, 3, 4, 8, and 24 hours post dose
Mean Maximum Serum Concentration (Cmax) of Paclitaxel When Administered in Combination With BIO 300
Time frame: Week 1 or 2, during the 1st or 2nd chemotherapy infusion, prior to BIO 300 dose then 0.5, 1, 2, 3, 4, 8 and 24 hours post initial dose
Mean Area Under the Serum Concentration Curve (AUC) of Paclitaxel When Administered in Combination With BIO 300
Time frame: Week 1 or 2, during the 1st or 2nd chemotherapy infusion, prior to BIO 300 dose then 0.5, 1, 2, 3, 4, 8 and 24 hours post initial dose
Mean Maximum Serum Concentration (Cmax) of Carboplatin When Administered in Combination With BIO 300
Time frame: Week 1 or 2, during the 1st or 2nd chemotherapy infusion, prior to BIO 300 dose then 0.5, 1, 2, 3, 4, 8 and 24 hours post initial dose
Mean Area Under the Serum Concentration Curve (AUC) of Carboplatin When Administered in Combination With BIO 300
Time frame: Week1 or 2, during the 1st or 2nd chemotherapy infusion, prior to BIO 300 dose then 0.5, 1, 2, 3, 4, 8 and 24 hours post initial dose
Percent Change From Baseline in Expression Levels of Serum TGF-beta Isoform 1 (TGFB1)
Measuring change from baseline (screening visit) of TGF-beta isoform 1 (TGFB1)
Time frame: Screening, once weekly during weeks 1-6 of concurrent chemoradiotherapy prior to BIO 300, paclitaxel, and carboplatin dose, and once at the end of consolidation, 3 months and 6 months after the completion of RT
Rate of Progressive Disease Evaluated by the Response Evaluation Criteria in Solid Tumors (RECIST) (1.1) Criteria
Best Response Rate reported per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by chest CT imaging: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Progressive Disease (PD), At least a 20% increase in the sum of diameters of target lesions; Stable Disease (SD), Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD.
Time frame: Screening, visits 20, 37, 38, 39, 40, 41 & 42 (through visit 41 for surgical participants)
Change in Tumor Diameter as Measured by Diagnostic Computerized Tomography (CT) Scan
Tumor diameter was measured in centimeters. Mean change in tumor diameter from the baseline measurement at screening is reported.
Time frame: Screening, visits 20 and 3, 6, 11 & 13 months post radiation therapy
DLCO as Measured by Pulmonary Function Test (PFT)
Time frame: Screening and months 6 & 13 post radiation therapy completion
Number of Participants With Pulmonary Fibrosis Assessed by Four-dimensional Computerized Tomography (4D-CT)
Time frame: Screening, visits 20 & 37 and 9 & 13 months post radiation therapy for non-surgical participants; screening only for surgical participants
Quality of Life (QOL) as Measured by Functional Assessment of Cancer Therapy-Lung Scale Trial Outcome Index (FACT-L TOI) Patient Reported Outcome Questionnaire.
The Functional Assessment of Cancer Therapy-Lung Scale Trial Outcome Index (FACT-L TOI) questionnaire is a 36-item self-reporting instrument that measures quality of life specific to patients with cancer. Items are rated on a 5 item (point) Likert Scale, from 0 (not at all) to 4 (very much). Total scores range from 0 to 136 and higher scores indicate better quality of life. The FACT-L TOI questionnaire was scored according to FACT-L Scoring Guidelines Version 4.
Time frame: Screening and months 3, 6, & 13 post radiation therapy completion
Quality of Life (QOL) as Measured by University of California, San Diego-Shortness of Breath Questionnaire (UCSD-SOBQ) Patient Reported Outcome Questionnaire.
The UCSD-SOBQ is a 24-item patient self-reported questionnaire where items are scored on a 6-point scale (0, "not at all" to 5, "maximal or unable to-do because of breathlessness"). Total scores range from 0 to 120 and lower scores indicate better quality of life.
Time frame: Screening and months 3, 6, & 13 post radiation therapy completion
Extent of Esophagitis by Patient Reported Swallowing Diary
The assessment will provide a score (the swallowing questionnaire) from 0 to 5; 1 no problems swallowing; 2 mild soreness only; 3 some difficulty swallowing solids; 4 cannot swallow solids; and 5 cannot swallow liquids.
Time frame: Screening, weeks 1, 2, 3, 4, 5, & 6 and months 3 & 6 post radiation therapy completion
Mean Weekly BIO 300 Trough Levels, Serum Concentration of BIO 300
Time frame: Concurrent chemoradiotherapy weeks 1, 2, 3, 4, 5 and 6
Weekly Paclitaxel Trough Levels, Plasma Concentration of Paclitaxel and Carboplatin
Serum trough levels of paclitaxel and carboplatin were measured. Carboplatin trough levels were below the limit of quantification at all timepoints and are therefore reported as NA (Not Available).
Time frame: Concurrent chemoradiotherapy weeks 1, 2, 3, 4, 5 and 6
FVC as Measured by Pulmonary Function Test (PFT)
Time frame: Screening and months 6 & 13 post radiation therapy completion
FEV1 as Measured by Pulmonary Function Test (PFT)
Time frame: Screening and months 6 & 13 post radiation therapy completion
| Milestone | BIO 300 Oral Suspension (500 mg/Day) | BIO 300 Oral Suspension (1000 mg/Day) | BIO 300 Oral Suspension (1500 mg/Day) |
|---|---|---|---|
| Started | 7 | 7 | 7 |
| Completed | 6 | 4 | 6 |
| Not completed | 1 | 3 | 1 |
| Withdrew: Death | 1 | 0 | 0 |
| Withdrew: Adverse event | 0 | 1 | 0 |
| Withdrew: Progressive disease | 0 | 2 | 1 |
| Milestone | BIO 300 Oral Suspension (500 mg/Day) | BIO 300 Oral Suspension (1000 mg/Day) | BIO 300 Oral Suspension (1500 mg/Day) |
|---|---|---|---|
| Started | 6 | 4 | 6 |
| Completed | 4 | 3 | 2 |
| Not completed | 2 | 1 | 4 |
| Withdrew: Death | 1 | 0 | 1 |
| Withdrew: Progressive disease | 1 | 1 | 3 |
Adverse events of CTCAE v4.0 grade 3 or higher that were possibly, probably or definitely related to BIO 300 Oral Suspension and have occurred before or during concurrent chemoradiotherapy were considered dose limiting toxicities.
| Participants | BIO 300 Oral Suspension (500 mg/Day) | BIO 300 Oral Suspension (1000 mg/Day) | BIO 300 Oral Suspension (1500 mg/Day) |
|---|---|---|---|
| Number of Participants Experiencing DLTs | 0 | 0 | 0 |
| Number of Participants That Did Not Experience a DLT | 6 | 7 | 7 |
| Participants | BIO 300 Oral Suspension (500 mg/Day) | BIO 300 Oral Suspension (1000 mg/Day) | BIO 300 Oral Suspension (1500 mg/Day) |
|---|---|---|---|
| Number of Participants With Adverse Events Throughout the Study | 7 | 7 | 7 |
| ng/mL | BIO 300 Oral Suspension (500 mg/Day) | BIO 300 Oral Suspension (1000 mg/Day) | BIO 300 Oral Suspension (1500 mg/Day) |
|---|---|---|---|
| Mean Maximum Serum Concentration (Cmax) of BIO 300 Administered in the Absence of Chemotherapy | 174 ± 74 | 302 ± 194 | 388 ± 264 |
| ng*hr/mL | BIO 300 Oral Suspension (500 mg/Day) | BIO 300 Oral Suspension (1000 mg/Day) | BIO 300 Oral Suspension (1500 mg/Day) |
|---|---|---|---|
| Mean Area Under the Serum Concentration Curve (AUC) of BIO 300 Administered in the Absence of Chemotherapy | 857 ± 341 | 1493 ± 1123 | 1570 ± 883 |
| ng/mL | BIO 300 Oral Suspension (500 mg/Day) | BIO 300 Oral Suspension (1000 mg/Day) | BIO 300 Oral Suspension (1500 mg/Day) |
|---|---|---|---|
| Mean Maximum Serum Concentration (Cmax) of BIO 300 When Administered in Combination With Paclitaxel and Carboplatin | 155 ± 30 | 427 ± 339 | 414 ± 257 |
| ng*hr/mL | BIO 300 Oral Suspension (500 mg/Day) | BIO 300 Oral Suspension (1000 mg/Day) | BIO 300 Oral Suspension (1500 mg/Day) |
|---|---|---|---|
| Mean Area Under the Serum Concentration Curve (AUC) of BIO 300 When Administered in Combination With Paclitaxel and Carboplatin | 1371 ± 1174 | 1578 ± 726 | 1821 ± 964 |
| ng/mL | BIO 300 Oral Suspension (500 mg/Day) | BIO 300 Oral Suspension (1000 mg/Day) | BIO 300 Oral Suspension (1500 mg/Day) |
|---|---|---|---|
| Mean Maximum Serum Concentration (Cmax) of Paclitaxel When Administered in Combination With BIO 300 | 665.5 ± 588.06 | 1026.5 ± 260.36 | 307.6 ± 288.2 |
| ng*hr/mL | BIO 300 Oral Suspension (500 mg/Day) | BIO 300 Oral Suspension (1000 mg/Day) | BIO 300 Oral Suspension (1500 mg/Day) |
|---|---|---|---|
| Mean Area Under the Serum Concentration Curve (AUC) of Paclitaxel When Administered in Combination With BIO 300 | 1236.51 ± 680.63 | 1796.1 ± 409.49 | 755.27 ± 306.45 |
| ng/mL | BIO 300 Oral Suspension (500 mg/Day) | BIO 300 Oral Suspension (1000 mg/Day) | BIO 300 Oral Suspension (1500 mg/Day) |
|---|---|---|---|
| Mean Maximum Serum Concentration (Cmax) of Carboplatin When Administered in Combination With BIO 300 | 7594 ± 1946.03 | 9938.33 ± 3452.58 | 12883.33 ± 7446.87 |
| ng*hr/mL | BIO 300 Oral Suspension (500 mg/Day) | BIO 300 Oral Suspension (1000 mg/Day) | BIO 300 Oral Suspension (1500 mg/Day) |
|---|---|---|---|
| Mean Area Under the Serum Concentration Curve (AUC) of Carboplatin When Administered in Combination With BIO 300 | 30810.04 ± 5729.8 | 41785.18 ± 11133.8 | 41753.3 ± 14462.78 |
Measuring change from baseline (screening visit) of TGF-beta isoform 1 (TGFB1)
| Percent change from baseline | BIO 300 Oral Suspension (500 mg/Day) | BIO 300 Oral Suspension (1000 mg/Day) | BIO 300 Oral Suspension (1500 mg/Day) |
|---|---|---|---|
| Week 1 | 141.8 ± 64.1 | 96.7 ± 5.1 | 117.3 ± 48.5 |
| Week 2 | 130.3 ± 79.9 | 127.5 ± 77.9 | 96.7 ± 38.8 |
| Week 3 | 108.6 ± 79.0 | 60.1 ± 40.1 | 74.4 ± 25.9 |
| Week 4 | 90.6 ± 66.0 | 69.0 ± 43.8 | 55.8 ± 19.9 |
| Week 5 | 88.5 ± 86.8 | 61.7 ± 44.3 | 51.2 ± 12.1 |
| Week 6 | 142.8 ± 133.9 | 69.3 ± 43.9 | 33.4 ± 33.5 |
| After consolidation therapy | 68.7 ± 44.2 | 74.3 ± 78.5 | 60.8 ± 28.4 |
| 3 months post-RT | 205.7 ± 161.2 | 144.9 ± 96.4 | 83.1 ± 18.7 |
| 6 months post-RT | 106.5 ± 57.4 | 130.5 ± 93.5 | 61.2 ± 36.6 |
Best Response Rate reported per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by chest CT imaging: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Progressive Disease (PD), At least a 20% increase in the sum of diameters of target lesions; Stable Disease (SD), Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD.
| Participants | BIO 300 Oral Suspension (500 mg/Day) | BIO 300 Oral Suspension (1000 mg/Day) | BIO 300 Oral Suspension (1500 mg/Day) |
|---|---|---|---|
| Complete Response | 0 | 2 | 2 |
| Partial Response | 5 | 2 | 2 |
| Stable Disease | 1 | 3 | 3 |
| Progressive Disease | 0 | 0 | 0 |
Tumor diameter was measured in centimeters. Mean change in tumor diameter from the baseline measurement at screening is reported.
| Mean Change from Baseline (cm) | BIO 300 Oral Suspension (500 mg/Day) | BIO 300 Oral Suspension (1000 mg/Day) | BIO 300 Oral Suspension (1500 mg/Day) |
|---|---|---|---|
| Visit 20 | -1.30 ± 1.20 | 0.04 ± 3.24 | -1.15 ± 1.63 |
| 3 Months Post-RT | -2.83 ± 1.35 | -2.29 ± 0.82 | -3.54 ± 1.86 |
| 6 Months Post-RT | -2.43 ± 0.99 | -3.23 ± 1.02 | -3.42 ± 2.08 |
| 9 Months Post-RT | -2.58 ± 0.87 | -3.25 ± 0.49 | -5.0 ± 1.75 |
| 11 Months Post-RT | -2.55 ± 0.95 | -3.10 ± 0.56 | -5.9 ± 0 |
| 13 Months Post-RT | -2.33 ± 1.31 | -3.13 ± 1.27 | -3.05 ± 5.02 |
| mL/mmHg/Min | BIO 300 Oral Suspension (500 mg/Day) | BIO 300 Oral Suspension (1000 mg/Day) | BIO 300 Oral Suspension (1500 mg/Day) |
|---|---|---|---|
| Baseline | 12.12 ± 3.80 | 14.96 ± 3.28 | 16.15 ± 6.60 |
| 6 months post-RT | 10.83 ± 4.31 | 10.46 ± 4.27 | 11.28 ± 5.82 |
| 13 months post-RT | 11.65 ± 4.61 | 9.48 ± 1.92 | 18.95 ± 1.09 |
| Participants | BIO 300 Oral Suspension (500 mg/Day) | BIO 300 Oral Suspension (1000 mg/Day) | BIO 300 Oral Suspension (1500 mg/Day) |
|---|---|---|---|
| Number of Participants With Pulmonary Fibrosis Assessed by Four-dimensional Computerized Tomography (4D-CT) | 0 | 0 | 0 |
The Functional Assessment of Cancer Therapy-Lung Scale Trial Outcome Index (FACT-L TOI) questionnaire is a 36-item self-reporting instrument that measures quality of life specific to patients with cancer. Items are rated on a 5 item (point) Likert Scale, from 0 (not at all) to 4 (very much). Total scores range from 0 to 136 and higher scores indicate better quality of life. The FACT-L TOI questionnaire was scored according to FACT-L Scoring Guidelines Version 4.
| FACT-L Total Score | BIO 300 Oral Suspension (500 mg/Day) | BIO 300 Oral Suspension (1000 mg/Day) | BIO 300 Oral Suspension (1500 mg/Day) |
|---|---|---|---|
| Screening | 66.6 ± 10.8 | 53.8 ± 21.5 | 53.9 ± 13.2 |
| 3 months post-RT | 54.5 ± 16.4 | 63.0 ± 6.7 | 55.6 ± 13.3 |
| 6 months post-RT | 55.4 ± 15.5 | 49.7 ± 13.5 | 51.4 ± 15.0 |
| 13 months post-RT | 50.8 ± 22.4 | 61.5 ± 18.1 | 55.0 ± 13.8 |
The UCSD-SOBQ is a 24-item patient self-reported questionnaire where items are scored on a 6-point scale (0, "not at all" to 5, "maximal or unable to-do because of breathlessness"). Total scores range from 0 to 120 and lower scores indicate better quality of life.
| UCSD-SOBQ Total Score | BIO 300 Oral Suspension (500 mg/Day) | BIO 300 Oral Suspension (1000 mg/Day) | BIO 300 Oral Suspension (1500 mg/Day) |
|---|---|---|---|
| Screening | 19.4 ± 17.4 | 29.9 ± 32.3 | 13.9 ± 11.9 |
| 3 months post-RT | 37.0 ± 33.5 | 38.0 ± 13.9 | 23.0 ± 20.8 |
| 6 months post-RT | 46.8 ± 31.1 | 54.7 ± 26.6 | 24.8 ± 20.8 |
| 13 months post-RT | 64.0 ± 43.6 | 39.8 ± 23.4 | 23.2 ± 18.0 |
The assessment will provide a score (the swallowing questionnaire) from 0 to 5; 1 no problems swallowing; 2 mild soreness only; 3 some difficulty swallowing solids; 4 cannot swallow solids; and 5 cannot swallow liquids.
| Swallowing Diary Score | BIO 300 Oral Suspension (500 mg/Day) | BIO 300 Oral Suspension (1000 mg/Day) | BIO 300 Oral Suspension (1500 mg/Day) |
|---|---|---|---|
| Weeks 1-6 Average | 1.2 ± 0.36 | 1.54 ± 0.41 | 1.64 ± 0.87 |
| 3 months post-RT | 1.0 ± 0 | 1.0 ± 0 | 1.6 ± 0.89 |
| 6 months post-RT | 1.33 ± 0.58 | 1.0 ± 0 | 1.6 ± 0.55 |
| ng/mL | BIO 300 Oral Suspension (500 mg/Day) | BIO 300 Oral Suspension (1000 mg/Day) | BIO 300 Oral Suspension (1500 mg/Day) |
|---|---|---|---|
| Week 1 | 44.2 ± 90.0 | — | 16.02 ± 23.7 |
| Week 2 | 32.6 ± 44.2 | 5.84 ± 8.8 | 9.96 ± 13.9 |
| Week 3 | 5.1 ± 4.5 | 5.56 ± 8.0 | 14.12 ± 18.6 |
| Week 4 | 8.3 ± 13.9 | 3.82 ± 6.0 | 22.66 ± 44.7 |
| Week 5 | 40.7 ± 36.2 | 6.71 ± 11.9 | 23.54 ± 38.0 |
| Week 6 | 12.4 ± 15.7 | 24.0 ± 32.5 | 24.54 ± 23.8 |
Serum trough levels of paclitaxel and carboplatin were measured. Carboplatin trough levels were below the limit of quantification at all timepoints and are therefore reported as NA (Not Available).
| ng/mL | Paclitaxel | Carboplatin |
|---|---|---|
| Week 1 | 1.04 ± 0.08 | NA ± NA |
| Week 2 | 1.09 ± 0.19 | NA ± NA |
| Week 3 | 1.53 ± 0.93 | NA ± NA |
| Week 4 | 1.83 ± 0.81 | NA ± NA |
| Week 5 | 1.90 ± 0.96 | NA ± NA |
| Week 6 | 1.92 ± 1.19 | NA ± NA |
| Liters | BIO 300 Oral Suspension (500 mg/Day) | BIO 300 Oral Suspension (1000 mg/Day) | BIO 300 Oral Suspension (1500 mg/Day) |
|---|---|---|---|
| Baseline | 2.46 ± 0.46 | 2.79 ± 0.56 | 3.51 ± 0.85 |
| 6 months post-RT | 2.32 ± 0.65 | 2.1 ± 0.60 | 2.93 ± 0.74 |
| 13 months post-RT | 2.32 ± 0.67 | 2.19 ± 0.44 | 3.28 ± 0.27 |
| Liters | BIO 300 Oral Suspension (500 mg/Day) | BIO 300 Oral Suspension (1000 mg/Day) | BIO 300 Oral Suspension (1500 mg/Day) |
|---|---|---|---|
| Baseline | 1.69 ± 0.38 | 1.91 ± 0.59 | 2.39 ± 0.83 |
| 6 months post-RT | 1.71 ± 0.53 | 1.29 ± 0.13 | 2.03 ± 0.60 |
| 13 months post-RT | 1.61 ± 0.55 | 1.26 ± 0.06 | 2.39 ± 0.27 |
Collected over Day 1 up to month 13 post radiation or 12 months post chemotherapy consolidation for surgical participants.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| BIO 300 Oral Suspension (500 mg/Day) | 2/7 (28.6%) | 3/7 (42.9%) | 7/7 (100%) |
| BIO 300 Oral Suspension (1000 mg/Day) | 0/7 (0%) | 1/7 (14.3%) | 7/7 (100%) |
| BIO 300 Oral Suspension (1500 mg/Day) | 1/7 (14.3%) | 2/7 (28.6%) | 7/7 (100%) |
| Event | BIO 300 Oral Suspension (500 mg/Day) | BIO 300 Oral Suspension (1000 mg/Day) | BIO 300 Oral Suspension (1500 mg/Day) |
|---|---|---|---|
| DyspneaRespiratory, thoracic and mediastinal disorders | 1/7 | 0/7 | 2/7 |
| Atrial FibrillationCardiac disorders | 0/7 | 0/7 | 1/7 |
| Cardiac ArrestCardiac disorders | 1/7 | 0/7 | 0/7 |
| Sinus TachycardiaCardiac disorders | 0/7 | 1/7 | 0/7 |
| DiarrheaGastrointestinal disorders | 1/7 | 0/7 | 0/7 |
| FeverGeneral disorders | 0/7 | 0/7 | 1/7 |
| CoughRespiratory, thoracic and mediastinal disorders | 0/7 | 0/7 | 1/7 |
| Thromboembolic EventVascular disorders | 1/7 | 0/7 | 1/7 |
| EsophagitisGastrointestinal disorders | 0/7 | 0/7 | 1/7 |
| DehydrationMetabolism and nutrition disorders | 0/7 | 0/7 | 1/7 |
| Event | BIO 300 Oral Suspension (500 mg/Day) | BIO 300 Oral Suspension (1000 mg/Day) | BIO 300 Oral Suspension (1500 mg/Day) |
|---|---|---|---|
| EsophagitisGastrointestinal disorders | 0/7 | 5/7 | 7/7 |
| White Blood Cell DecreasedInvestigations | 1/7 | 6/7 | 2/7 |
| Neutrophil Count DecreasedInvestigations | 3/7 | 5/7 | 1/7 |
| Platelet Count DecreasedInvestigations | 2/7 | 5/7 | 2/7 |
| FatigueGeneral disorders | 2/7 | 3/7 | 4/7 |
| Radiation DermatitisInjury, poisoning and procedural complications | 1/7 | 2/7 | 4/7 |
| Lymphocyte DecreasedInvestigations | 0/7 | 4/7 | 3/7 |
| PneumonitisRespiratory, thoracic and mediastinal disorders | 1/7 | 4/7 | 3/7 |
| ConstipationGastrointestinal disorders | 2/7 | 3/7 | 1/7 |
| DysphagiaGastrointestinal disorders | 2/7 | 2/7 | 3/7 |
| Age, Continuous(years) | BIO 300 Oral Suspension (500 mg/Day) | BIO 300 Oral Suspension (1000 mg/Day) | BIO 300 Oral Suspension (1500 mg/Day) | Total |
|---|---|---|---|---|
| Median | 78 (69 to 84) | 69 (57 to 83) | 57 (50 to 76) | 69 (50 to 84) |
| Sex: Female, Male(Participants) | BIO 300 Oral Suspension (500 mg/Day) | BIO 300 Oral Suspension (1000 mg/Day) | BIO 300 Oral Suspension (1500 mg/Day) | Total |
|---|---|---|---|---|
| Female | 5 | 5 | 1 | 11 |
| Male | 2 | 2 | 6 | 10 |
| Ethnicity (NIH/OMB)(Participants) | BIO 300 Oral Suspension (500 mg/Day) | BIO 300 Oral Suspension (1000 mg/Day) | BIO 300 Oral Suspension (1500 mg/Day) | Total |
|---|---|---|---|---|
| Hispanic or Latino | 1 | 2 | 0 | 3 |
| Not Hispanic or Latino | 6 | 5 | 7 | 18 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | BIO 300 Oral Suspension (500 mg/Day) | BIO 300 Oral Suspension (1000 mg/Day) | BIO 300 Oral Suspension (1500 mg/Day) | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 1 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 1 | 0 | 0 | 1 |
| White | 6 | 7 | 6 | 19 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Region of Enrollment(participants) | BIO 300 Oral Suspension (500 mg/Day) | BIO 300 Oral Suspension (1000 mg/Day) | BIO 300 Oral Suspension (1500 mg/Day) | Total |
|---|---|---|---|---|
| United States | 7 | 7 | 7 | 21 |
| Initial Tumor Stage(Participants) | BIO 300 Oral Suspension (500 mg/Day) | BIO 300 Oral Suspension (1000 mg/Day) | BIO 300 Oral Suspension (1500 mg/Day) | Total |
|---|---|---|---|---|
| Stage II | 2 | 2 | 1 | 5 |
| Stage III | 5 | 5 | 4 | 14 |
| Stage IV | 0 | 0 | 2 | 2 |
| Tumor Histology(Participants) | BIO 300 Oral Suspension (500 mg/Day) | BIO 300 Oral Suspension (1000 mg/Day) | BIO 300 Oral Suspension (1500 mg/Day) | Total |
|---|---|---|---|---|
| Squamous | 3 | 3 | 4 | 10 |
| Adenocarcinoma | 4 | 4 | 3 | 11 |
| Primary Tumor Location(Participants) | BIO 300 Oral Suspension (500 mg/Day) | BIO 300 Oral Suspension (1000 mg/Day) | BIO 300 Oral Suspension (1500 mg/Day) | Total |
|---|---|---|---|---|
| Left Upper Lobe | 3 | 3 | 1 | 7 |
| Left Lower Lobe | 0 | 1 | 2 | 3 |
| Right Upper Lobe | 3 | 2 | 4 | 9 |
| Right Middle Lobe | 0 | 1 | 0 | 1 |
| Right Lower Lobe | 1 | 0 | 0 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
The record gives a start of Nov 2015, a primary completion of Apr 2019 and a completion of Sep 2020. It does not say whether these dates are actual or estimated.
Results were first posted in Dec 2023, 4 years 8 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Genistein-based BIO 300
Carcinoma, Non-Small-Cell Lung →
Humanetics Corporation